Company Overview
Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.18.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $701.20M (+1.9% YoY); net profit $-72.90M.
- Trailing 12 Months Year-on-year growth — revenue +8.8%, earnings -21.7%.
- 5-Year Trend Long-term compounding — revenue CAGR -6.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -6.52% |
| 1 Year: | 8.80% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -21.70% |
Stock Price Performance
| 1 Year: | +0.08% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Generates positive free cash flow.
CONS
- Revenue declined at -6.5% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | AVNS Avanos Medical Inc R2KPHARMA | 24.99 | -15.62 | $1.17B | 0.00% | 1.70% | -9.18% | -6.52% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2013 | Mar 2014 | Jun 2014 | Sep 2014 | Mar 2015 | Jun 2015 | Sep 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | 145.70M | 149.10M | 150.50M | 156.40M | 160.90M | 165.10M | 164.20M | 172.20M | 171.40M | 180.40M | 163.70M | 185.70M | 180.70M | 186.40M | 184.10M | 197.40M | 170.90M | 172.30M | 159.30M | 169.40M | 171.30M | 166.10M | 171.70M | 170.40M | - | 167.50M | 175.00M | 177.80M | 180.90M | 182.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 77.70M | 82.90M | 91.80M | 94.90M | 88.00M |
| Gross Profit | 161.50M | 155.00M | 104.90M | 132.20M | 132.10M | 134.90M | 131.00M | 136.50M | 140.70M | 138.00M | 81.50M | 84.50M | 81.00M | 91.10M | 94.70M | 104.70M | 98.80M | 98.70M | 95.00M | 102.10M | 86.50M | 95.80M | 91.30M | 85.70M | 90.20M | 106.60M | 101.60M | 100.20M | 91.40M | 97.80M | 95.50M | 94.80M | 95.60M | 92.90M | - | 89.80M | 92.10M | 86.00M | 86.00M | 94.20M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 79.50M | 89.60M | 85.90M | 83.50M | 85.30M |
| Operating Income | 70.30M | 61.70M | -4.50M | 13.10M | 40.90M | 22.10M | -461.20M | 33.10M | 17.60M | 20.90M | -17.60M | -12.10M | -10.40M | -7.00M | 8.80M | 7.00M | -24.60M | -9.80M | -18.10M | 600.00K | -1.80M | -100.00K | -12.40M | -7.30M | 3.40M | 8.60M | 10.10M | 12.80M | -6.10M | -2.10M | 1.20M | 4.00M | 6.30M | 12.00M | - | 10.30M | 2.50M | 100.00K | 2.50M | 8.90M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 21.40M | -63.90M | 10.00M | 13.00M | 19.30M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.10M | 2.00M | 1.80M | 1.90M | 1.50M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 9.70M | -75.90M | -1.20M | 1.20M | 7.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.10M | 900.00K | 200.00K | 2.50M | 2.50M |
| Net Income | 47.90M | 41.40M | -4.50M | -7.40M | 21.70M | 8.00M | -470.50M | 14.20M | 6.50M | 9.10M | 12.80M | 17.10M | 16.60M | 20.20M | 35.30M | 4.20M | -20.30M | -8.00M | -11.50M | 3.70M | -3.00M | 19.30M | -8.40M | 38.50M | -35.30M | 5.40M | 12.50M | 15.70M | -500.00K | -68.10M | -3.70M | -900.00K | 1.80M | 4.30M | - | 6.60M | -76.80M | -1.40M | -1.30M | 5.10M |
| Diluted EPS | - | 0.89 | -0.10 | -0.16 | 0.46 | 0.17 | -10.10 | 0.30 | 0.14 | 0.19 | 0.27 | 0.37 | 0.35 | 0.43 | 0.73 | 0.09 | -0.43 | -0.17 | -0.24 | 0.08 | -0.06 | 0.40 | -0.17 | 0.79 | -0.73 | 0.11 | 0.26 | 0.33 | -0.01 | -1.46 | -0.08 | -0.02 | 0.04 | 0.09 | - | 0.14 | -1.66 | -0.03 | -0.03 | 0.11 |
| R&D Expense | 8.90M | 8.30M | 9.30M | 8.50M | 6.00M | 6.30M | 10.20M | 8.70M | 9.50M | 10.90M | 7.30M | 9.20M | 9.60M | 9.90M | 10.80M | 10.50M | 10.20M | 9.50M | 9.60M | 9.40M | 7.70M | 8.20M | 8.30M | 8.00M | 8.40M | 7.80M | 7.60M | 7.10M | 7.50M | 6.80M | 6.10M | 7.00M | 6.30M | 7.20M | - | 5.40M | 5.80M | 6.00M | - | 5.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.68B | 1.68B | 1.67B | 509.00M | 566.20M | 611.60M | 652.30M | 697.60M | 714.80M | 587.00M | 684.10M | 673.30M | 687.80M | 701.20M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 289.90M | 293.60M | 306.50M | 347.30M |
| Gross Profit | 602.50M | 612.20M | 548.60M | 257.80M | 297.20M | 336.90M | 390.90M | 402.20M | 370.90M | 299.20M | 394.20M | 379.70M | 381.30M | 353.90M |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 358.70M | 375.50M | 340.80M | 338.50M |
| Operating Income | 228.00M | 225.30M | 94.30M | -135.70M | -107.10M | -43.10M | 500.00K | -55.70M | -48.50M | -39.00M | 35.50M | 4.20M | 40.50M | 15.40M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 84.40M | 53.20M | -345.60M | -19.50M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 10.00M | 15.00M | 12.20M | 7.80M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | 26.70M | -7.90M | -403.30M | -66.20M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 5.20M | 2.00M | -17.00M | 6.70M |
| Net Income | 152.60M | 154.60M | 27.10M | -426.30M | 39.80M | 79.30M | 57.50M | -45.90M | -29.00M | 6.30M | 50.50M | -61.80M | -392.10M | -72.90M |
| Diluted EPS | 3.28 | 3.32 | 0.58 | -9.15 | 0.85 | 1.69 | 1.22 | -0.96 | -0.61 | 0.13 | 1.07 | -1.32 | -8.53 | -1.57 |
| R&D Expense | 33.00M | 37.90M | 33.60M | 27.60M | 38.40M | 38.20M | 41.80M | 37.70M | 34.90M | 30.60M | 29.20M | 27.20M | 26.20M | 23.30M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.48B | 2.52B | 2.00B | 2.07B | 2.20B | 1.83B | 1.80B | 1.67B | - | 1.79B | 1.69B | 1.15B | 1.07B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | 624.10M | 487.00M | 393.40M | 355.40M |
| Cash & Equivalents | 20.10M | 47.90M | 44.10M | 149.00M | 129.50M | 113.70M | 219.70M | 384.50M | 205.30M | 111.50M | - | 127.70M | 87.70M | 107.70M | 89.80M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | 132.30M | 163.20M | 138.80M | 148.00M |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | 155.70M | 128.70M | 127.90M | 103.70M |
| Total Liabilities | - | - | 404.90M | 1.03B | 944.90M | 969.30M | 980.50M | 536.20M | 534.40M | 416.30M | - | 495.70M | 456.10M | 325.70M | 295.50M |
| Current Liabilities | - | - | 310.40M | 356.00M | 315.20M | 324.40M | 389.80M | 264.30M | 212.50M | 166.30M | - | 191.00M | 234.60M | 165.90M | 165.20M |
| Long Term Debt | - | - | 0 | 622.60M | 578.10M | 579.00M | 541.10M | 247.70M | 248.10M | 180.00M | - | 226.30M | 159.40M | 125.30M | 90.30M |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | 277.00M | 209.10M | 170.20M | 129.10M |
| Total Equity | 2.00B | 2.06B | 2.08B | 1.49B | 1.06B | 1.10B | 1.22B | 1.30B | 1.27B | 1.26B | - | 1.29B | 1.24B | 828.50M | 778.20M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | 46.53M | 46.17M | 45.96M | 50.39M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | 202.60M | 223.80M | 147.90M | 97.60M | 188.80M | 144.20M | -145.60M | -74.50M | -2.50M | - | 90.90M | 32.40M | 100.70M | 74.70M |
| Investing Cash Flow | -40.30M | -50.90M | -70.70M | -62.60M | -200.90M | -43.10M | 639.50M | -108.10M | -24.20M | - | -135.40M | 21.60M | -27.50M | -60.60M |
| Financing Cash Flow | -133.90M | -180.00M | 29.20M | -50.60M | -1.40M | 2.20M | -324.40M | 1.50M | -70.00M | - | 56.70M | -94.20M | -49.10M | -37.00M |
| Capital Expenditure | - | - | - | - | - | - | - | - | - | - | -19.30M | -17.80M | -17.80M | -31.60M |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - | 71.60M | 14.60M | 82.90M | 43.10M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | 12.20M | -40.20M | 24.10M | -22.90M |
| Share Buybacks | - | 0 | 0 | 1.00M | 900.00K | 2.50M | 900.00K | 3.60M | 900.00K | 11.50M | 45.50M | 19.10M | 12.80M | 3.30M |
| Dividends Paid | - | - | - | - | - | - | 0 | - | - | - | - | - | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 35.8% | 36.5% | 32.8% | 50.6% | 52.5% | 55.1% | 59.9% | 57.7% | 51.9% | 51.0% | 57.6% | 56.4% | 55.4% | 50.5% |
| Operating Margin % | 13.5% | 13.4% | 5.6% | -26.7% | -18.9% | -7.0% | 0.1% | -8.0% | -6.8% | -6.6% | 5.2% | 0.6% | 5.9% | 2.2% |
| Net Margin % | 9.1% | 9.2% | 1.6% | -83.8% | 7.0% | 13.0% | 8.8% | -6.6% | -4.1% | 1.1% | 7.4% | -9.2% | -57.0% | -10.4% |
| ROE % | 7.4% | 7.4% | 1.8% | -40.4% | 3.6% | 6.5% | 4.4% | -3.6% | -2.3% | - | 3.9% | -5.0% | -47.3% | -9.4% |
| ROCE % | - | 10.4% | 4.4% | -8.1% | -6.1% | -2.4% | 0.0% | -3.5% | -3.2% | - | 2.2% | 0.3% | 4.1% | 1.7% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 14.61% | 6.84M | $171.02M |
| 2 | T. Rowe Price Investment Management, Inc. | 11.38% | 5.33M | $133.22M |
| 3 | Brown Advisory Inc. | 4.76% | 2.23M | $55.76M |
| 4 | Dimensional Fund Advisors LP | 4.38% | 2.05M | $51.29M |
| 5 | Armistice Capital, LLC | 4.27% | 2.00M | $49.98M |
| 6 | Vanguard Capital Management LLC | 4.21% | 1.97M | $49.28M |
| 7 | State Street Corporation | 4.21% | 1.97M | $49.29M |
| 8 | Vanguard Portfolio Management LLC | 2.65% | 1.24M | $30.97M |
| 9 | Acadian Asset Management. LLC | 2.59% | 1.21M | $30.36M |
| 10 | Thrivent Financial For Lutherans | 2.54% | 1.19M | $29.69M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for AVNS
Avanos Medical Will Become Private With AIP Deal Complete - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxPUDVVTGVSSzNCRUhCeVQtZ3pxRm1YaXJVTWJQZ0JaODBkNXBFMEdNZzlyTlozMjZKdXc4MV9jU0ROWk5SOUYwcFAtWFBSZ1dIcEJ2WjV5Y1NkWUpBOURiQnZhelhPOENtbzYtYWlTenFnVU9iOHNZNElNYnktUkdHSk9jekxYXzBPTENXWj…
Avanos Stock Surged on $1.27 Billion AIP Buyout Deal at 72% Premium - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxNU3docHR1VGFsZ0xXSkMyVUh3bkxZUGtxQ2tqRm12b05HZlBMM2w5RVNOX0tTMVFVSjJCLUw0TjBCdXU4ZXJBY0laVlhwcVROZEEwOUxRYndXVHctdEJaWEZiVS16N3Qxc0pWaDdQSkVRSms1OGRva25xRm4tUmQ2N1l3cXRBaGRRZDIwdm…
Avanos Medical, Inc. Agrees To Be Acquired by American Industrial Partners for Approximately $1.272 Billion - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi8gFBVV95cUxPSDB5Qko3Znd3ZnUxbFVZZWR4eTNQNTM2aW54SWVMOVlXSFFVMWFCS2dTd1BrV3NreEtUMmwwOHpJVG92V0ZYMUFjUndHMk9zcXRQNFEwY2lpUWZOdFlSTDBnd3lxM2dTT0dyQ3ROTGZlOFltbkY4SDJQemhQQnhVR09zTUNGVXV1YUM0em…
Avanos Medical jumps on $25-per-share take-private agreement | AVNS Stock News - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMimwFBVV95cUxOTjllQWZrN05UdDU4bmVRTUN3eWxZM1VZUFAyZVNSX3BDeDUta24wdGtSeGJXMnkyd3dqcHM4YkhmZHh4NE5PRnoxa0kxZFlqdnFPTzVSUEVlLWZ2dGtYSDRhZ1pUYWZpMDJSc3dvZUtTeS15c0pya2FFWHh3YzU5aGF1YXNydk12OTVGak…
Avanos Medical Stock Looks Capped After American Industrial Partners' Offer (NYSE:AVNS) - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMitgFBVV95cUxOeUVYaTlub2NUMUJ3dDhmVWxETWVjTnpHb3Y1VTR1Mnlod0FnczhnTXltcXA5d0ExNjBTYk41UFFwWE9GNi1DUGpkZ2VhVzFzVzRkTnoySnBHeWZpZjEtVnl0N2M4TFRiRUN4Nk9WblVzNmVaUmdhM0ZaWm85blg0YTgyT0FLSzdGM2NYSH…
AVNS Stock Records Historic Intraday Surge – Everything To Know About The Buyout Deal By American Industrial Partners - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiiwJBVV95cUxOTm1td0N4eHVnQ05mOFJFN2RlbmxMVVdLbHZkeTQ5d0VReWhmNTZxZ2xpdzMzaWJWUWkwbVpKbEh4SUI1NmZYR085RHVjSzhNQnNuYWNBd3paa0ZGYWV0c3lwTE1tcUNPWEJvUk9JY0d4bDdWLV83SDVuVlpmN2dQMTBIVUg0LTJJRzNWWW…
AVNS — Frequently Asked Questions
What is the current share price of Avanos Medical Inc (AVNS)?
As of 2026-09-07 16:24 PDT, Avanos Medical Inc (AVNS) trades at $24.99 on NYSE. Its 52-week range is $24.97 to $24.99.
What is the market capitalisation of AVNS?
Avanos Medical Inc (AVNS) has a market capitalisation of $1.17B on NYSE.
What is the P/E ratio of AVNS?
AVNS trades at a trailing price-to-earnings (P/E) ratio of -15.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.49.
What is the return on equity (ROE) of AVNS?
AVNS has a return on equity (ROE) of -9.18%. Its return on capital employed (ROCE) is 1.70%.
Is AVNS a good stock to buy?
This page provides a data-driven analysis of Avanos Medical Inc (AVNS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.